Herman Silljé

Herman Silljé obtained his Ph.D. biotechnology at the University of Utrecht in the Netherlands. He completed a postdoctoral fellowship at the University of Geneva in Switzerland, and worked as a group leader at the Max Planck Institute for Biochemistry  in Germany. He was  scientific director of Kiadis Pharma, a biopharmaceutical company focused on cell-based immunotherapy, which was acquired by Sanofi.

During the last 12 years Dr. Silljé has been in charge of the preclinical cardiology laboratory at the UMCG in Groningen and is associate professor in the division of Experimental Cardiology at the UMCG Cardiology Research Institute. His main research interests are heart failure and inherited cardiomyopathy and the use of pre-clinical study models to investigate these diseases. A strong focus is on PLN-R14del cardiomyopathy, which is a major cause of inherited DCM and ACM in the Netherlands.